
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Doug Long, vice president of industry relations at IMS Health, discusses if health care providers will be hesitant to prescribe biosimilars.
Doug Long, vice president of industry relations at IMS Health, discusses if health care providers will be hesitant to prescribe biosimilars.
This video was recorded at the 2015 NACDS Total Store Expo.






